Roche’s New 2.3 Billion Dollar Bet on Nurix’s Blood Cancer Degrader

Roche Holding AG (OTC: RHHBY)  is making a major push deeper into targeted protein degradation, signing a deal worth up to 2.3 billion dollars with Nurix Therapeutics Inc. (NASDAQ: NRIX) for rights to an experimental blood cancer drug called bexobrutideg. The agreement gives Swiss‑based Roche a high‑potential oral therapy aimed at patients whose cancers stop responding to existing Bruton’s tyrosine kinase (BTK) inhibitors, while giving Nurix a large upfront payment and shared economics if the drug succeeds.

Deal terms and economics

The collaboration centers on bexobrutideg, an investigational BTK “degrader” designed to bind and remove disease‑driving proteins rather than just inhibit them. Under the agreement, Nurix will receive 700 million dollars in upfront cash from Roche, with the total value of the deal reaching up to 2.3 billion dollars if development, regulatory, and sales milestones are achieved.

Roche and Nurix will share development costs, with Roche covering 60 percent and Nurix 40 percent. In the United States, the companies will co‑commercialize bexobrutideg and split profits and losses 50/50, giving Nurix meaningful long‑term upside if the drug is successful. Outside the U.S., Roche will handle commercialization and pay Nurix tiered royalties on net sales. The deal is expected to close in the third quarter of 2026, subject to customary regulatory approvals.

What bexobrutideg targets

Bexobrutideg is being developed primarily for blood cancers such as chronic lymphocytic leukemia (CLL), where patients often receive BTK inhibitors but may eventually develop resistance. As a BTK degrader, bexobrutideg aims to eliminate the mutant BTK protein and potentially overcome resistance mechanisms that limit the durability of current therapies.

Roche and Nurix plan to begin a phase 3 clinical trial of bexobrutideg in CLL this summer, positioning the drug for a potential launch around the end of the decade if pivotal data are positive. Beyond CLL, the companies see potential in other hematologic malignancies and possibly immune or neurological diseases where BTK plays a role, which helps justify the size of the overall deal.

Why this matters for NRIX and Roche investors

For Nurix Therapeutics, the 700 million dollar upfront payment is transformative: it meaningfully strengthens the balance sheet, reduces near‑term funding pressure, and validates its targeted protein degradation platform with a top‑tier pharma partner. NRIX shares jumped sharply on the news, with premarket gains reported near 70 percent as investors priced in the de‑risking impact of the deal and the long‑term revenue potential from 50/50 U.S. profit sharing.

For Roche, the collaboration fits its strategy of bolting on high‑potential pipeline assets in oncology, particularly in areas like CLL where the company already has a strong presence and sees room for better options as resistance to current drugs grows. The deal also underscores Roche’s commitment to protein degradation technologies as a possible “next wave” after traditional small molecules and antibodies, even though clinical and regulatory risks for bexobrutideg still lie ahead.